Abstract

Background. Recent data demonstrated that the −174 G > C IL-6 polymorphism may account for differences in the therapeutic response to laparoscopic adjustable gastric banding (LAGB) surgery. Objective. We investigated the impact of −174 G > C IL-6 polymorphism on weight loss, body composition, and fluid distribution changes in obese subjects after LAGB. Design and Outcome Measures. Twenty obese subjects were selected and studied at baseline and 3 months after LAGB. Genetic assessment of −174 G > C IL-6 polymorphism and anthropometric and bioelectrical impedance analysis were performed. Results. At baseline, C(+) carriers had a lower extracellular water (ECW) and higher intra-CW, phase angle (PA), reactance Xc, and Xc/height. LAGB surgery determined significant reductions in weight and BMI. After LAGB, in C(−) carriers, significant decreases in weight, BMI, and ECW and increases in BCM, BCMI, ICW, PA, and Xc/H were highlighted. In C(+) carriers, significant reductions in weight, BMI, ICW, and PA and increases in ECW, Na/K, resistance (R), and R/height were obtained. Significant higher reductions in BMI and Xc/H were observed in C(+) with respect to C(−) carriers. Conclusions. Genotyping of genetic variants, for example, the −174 G > C polymorphism of IL-6, gives the opportunity to predict therapeutic response, in terms of body composition outcomes after LAGB.

Highlights

  • Assessment of body composition plays an important role in clinical evaluation and in monitoring absolute and relative changes during specific therapeutic regimens in obese subjects [1]

  • We investigated the impact of −174 G > C IL6 polymorphism on weight loss, body composition, and fluid distribution changes in obese subjects after laparoscopic adjustable gastric banding (LAGB)

  • We recently provided evidence that the promoter polymorphism of IL-6 (−174 G > C) gene is associated both with body composition and fluid distribution, in obese subjects, at baseline and at 6-month follow-up after LAGB, suggesting that LAGB was less effective if the subjects were carrying risk genotypes (C-carriers) for obesity [10]

Read more

Summary

Introduction

Assessment of body composition plays an important role in clinical evaluation and in monitoring absolute and relative changes during specific therapeutic regimens in obese subjects [1]. The weight losses induced by dietary or surgical treatment are more rapid in the first months and are associated with changes in body composition and fluid distribution [2]. Along with the increased acceptance of surgical procedures for weight loss in obesity, clinically useful baseline and follow-up measures of body composition and fluid distribution are critical to evaluate interventional outcomes. We investigated the impact of −174 G > C IL6 polymorphism on weight loss, body composition, and fluid distribution changes in obese subjects after LAGB. After LAGB, in C(−) carriers, significant decreases in weight, BMI, and ECW and increases in BCM, BCMI, ICW, PA, and Xc/H were highlighted. In C(+) carriers, significant reductions in weight, BMI, ICW, and PA and increases in ECW, Na/K, resistance (R), and R/height were obtained. Genotyping of genetic variants, for example, the −174 G > C polymorphism of IL-6, gives the opportunity to predict therapeutic response, in terms of body composition outcomes after LAGB

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call